Liver cirrhosis induces renal and liver phospholipase A2 activity in rats

Journal of Clinical Investigation

Volumn 98, Issue 2, 1996, Pages 365-371

  Vishwanath, Bannikuppe S ^a   Frey, Felix J ^a   Escher, Geneviève ^a   Reichen, Jürg ^a   Frey, Brigitte M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

annexins; bile salts; cirrhosis; mesangial cells; phospholipase A2

Indexed keywords

BILE SALT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1BETA; KIDNEY ENZYME; LIPOCORTIN 1; LIVER ENZYME; MESSENGER RNA; PHOSPHOLIPASE A2; PROSTAGLANDIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; IMMUNOBLOTTING; LIVER CIRRHOSIS; MALE; MESANGIUM CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT;

EID: 0030017255     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118801     Document Type: Article

References (75)

1. Kowalski, H.J., and W.H. Abelmann. 1953. Cardiac output at rest in Laennec's cirrhosis. J. Clin. Invest. 32:1025-1033.
2. Murray, J.F., A.M. Dawson, and S. Sherlock. 1958. Circulatory changes in chronic liver disease. Am. J. Med. 24:358-367.
3. Lieberman, F.L, and T.B. Reynolds. 1967. Plasma volume in cirrhosis of the liver. Its relation to portal hypertension, ascites and renal failure. J. Clin. Invest. 46:1297-1308.
4. Arroyo, V., J. Bosch, M. Mauri, F. Ribera, F. Navarro-Lopez, and J. Rodes. 1981. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur. J. Clin. Invest. 11:221-229.
5. Daoud, F.S., J.T. Reeves, and J.W. Schaefer. 1972. Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis. J. Clin. Invest. 51:1076-1080.
6. Ames, R.P., A.J. Borkowski, A.M. Sicinski, and J.H. Laragh. 1965. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J. Clin. Invest. 44:1171-1186.
7. Schroeder, E.T., G.H. Anderson, S.H. Goldman, and D.H.P. Streeten. 1976. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int. 9:511-519.
8. Krowka, M.J., and D.A. Cortese. 1990. Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. Hepatology. 11:138-142.
9. Davidson, E.W., and M.J. Dunn. 1987. Pathogenesis of the hepatorenal syndrome. Annu. Rev. Med. 38:361-372.
10. Green, J., and O.S. Better. 1995. Systemic hypotension and renal failure in obstructive jaundice - mechanistic and therapeutic aspects. JASN. 5:1853-1871.
11. Ohara, N., N.F. Voelkel, and S-W. Chang. 1993. Tissue eicosanoids and vascular permeability in rats with chronic biliary obstruction. Hepatology. 18: 111-118.
12. Reeves, J.T., and R.R. Grover. 1974. Blockade of acute hypoxic pulmonary hypertension by endotoxin. J. Appl. Physiol. 36:328-332.
13. Chang, S., C.O. Feddersen, P.M. Henson, and N.F. Voelkel. 1987. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J. Clin. Invest. 79:1498-1509.
14. Parker, M.M., J.H. Shelhamer, C. Natanson, W. Alling, and J.E. Parrillo. 1987. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit. Care Med. 15:923-929.
15. Zipser, R.D., J.C. Hoefs, P.F. Speckart, P.K. Zia, and R. Horton. 1979. Prostaglandins: modulator of renal function and presser resistance in chronic liver disease. J. Clin. Endocr. Metab. 48:895-900.
16. Bruix, J.J., D. Bopsch, R. Kravetz, R. Mastai, and J. Rodes. 1985. Effects of prostaglandin inhibition of systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology.. 88:430-435.
17. 2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology.. 84:697-703.
18. Guarner, F., C. Guarner, J. Prieto, I. Colina, J. Quiroga, J. Casas, R. Freixa, J. Rosello, E. Gelpi, and J. Balanzo. 1986. Increased synthesis of systemic prostaglandin in cirrhotic patients. Gastroenterology.. 90:687-694.
19. 2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenierology. 100:1069-1077.
20. Raymond, K.H., and M.D. Lifschitz. 1986. Effect of prostaglandins on renal salt and water excretion. Am. J. Med. 80:22-33.
21. Dibona, G.F. 1986. Prostaglandins and nonsteroidal anti-inflammatory drugs. Effects on renal hemodynamics. Am. J. Med. 80:12-21.
22. Wong, F., D. Massie, P. Hsu, and F. Dudley. 1994. Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. Gastroenterology. 106:658-663.
23. Gross, J.B. Jr., J. Reichen, T.B. Zeltner, and A. Zimmermann. 1987. The evolution of changes in quantitative liver function tests in a rat model of biliary cirrhosis: correlation with morphometric measurement of hepatocyte mass. Hepatology. 7:457-463.
24. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
25. 2. Biochem. Biophys. Res. Commun. 162:1030-1036.
26. Ohara, O., M. Tamaki, E. Nakamura, Y. Tsuruta, Y. Fjuii, M. Shin, H. Teraoka, and M. Okamoto. 1986. Dog and rat pancreatic phospholipases A2: Complete amino acid sequences deduced from complementary DNAs. J. Biochem. 99: 733-739.
27. Wallner, B.P., R.J. Mattaliano, C. Hession, R.L. Cate, R. Tizard, L.K. Sinclair, C. Foeller, E.P. Chow, J.L Browning, K.L. Ramachandran, and R.B. Pepinsky. 1986. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature (Lond.). 320:77-81.
28. Muller, S., and H.J. Seitz. 1994. Cloning of a cDNA for the FAD/linked glycerol/3/phosphate dehydrogenase from rat liver and its regulation by thyroid hormones. Proc. Natl. Acad. Sci. USA. 91:10581-10585.
29. 2 activity in rats. J. Clin. Invest. 92:1974-1980.
30. Sarkar, G., and S.S. Sommer. 1990. Shedding light on PCR contamination. Nature (Lond.). 343:27.
31. 2 in human polymorphonuclear leukocytes. Biochim. Biophys. Acta. 879:149-156.
32. Koehler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (Lond.). 256:495-497.
33. Frey, B.M., F.J. Frey, V.R. Lingappa, and H. Trachsel. 1991. Expression of human recombinant lipocortin I in a wheat-germ cell-free system and Xenopus oocytes. Biochem. J. 275:219-225.
34. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. SDS-polyacrylamide gel electrophoresis of proteins. In Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 18.47-18.59.
35. Lovett, D.H., R.B. Sterzel, M. Kashgarian, and J.L. Ryan. 1983. Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. Kidney Int. 23:342-349.
36. Patriarca, P., S. Beckerdite, and P. Elsbach. 1972. Phospholipases and phospholipid turnover in Escherichia coli spheroplasts. Biochim. Biophys. Acta. 260:593-600.
37. 2 enzyme. Nephrol. Dial. Transplant. 11:109-116.
38. 2 activities in human platelet, monocyte, and neutrophil. Biochem. Cell Biol. 71:331-339.
39. + exchange is activated at transcriptional and posttranscriptional level in rat biliary cirrhosis. Gastroenterology. 107:468-478.
40. Wang, A.M., M.V. Doyle, and D.F. Mark. 1989. Quantification of mRNA by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA. 86:9717-9721.
41. 2-alpha from the venom of Crotalus adamanteus. J. Biol. Chem. 252:4913-4921.
42. 2(s); comparison of arachidonoyl-selective and -nonselective enzymes. FASEB J. 7:339-348.
43. 2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett. 261:171-174.
44. 2 in human acute pancreatitis. Gastroenterology. 97:1521-1526.
45. 2. J. Biol. Chem. 264:5768-5775.
46. 2 activating protein (PLAP) and melittin. Biochim. Biophys. Acta. 1166:124-130.
47. 2 inhibitor which prevents prostaglandin generation. Nature (Lond.). 278:456-459.
48. Blackwell, G.J., R. Carnuccio, M. Di Rosa, R.J. Flower, L. Parente, and P. Persico. 1980. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature (Lond.). 287:147-149.
49. Goulding, N.J., and P.M. Guyre. 1993. Glucocorticoids, lipocortins and the immune response. Curr. Opin. Immunol. 5:108-113.
50. Cirino, G., S.H. Peers, R.J. Flower, J.L. Browning, and R.B. Pepinsky. 1989. Human recombinant lipocortin-1 has acute local antiinflammatory properties in the rat paw edema test. Proc. Natl. Acad. Sci. USA. 86:3428-3432.
51. Sautebin, L., R. Carnuccio, A. Ialenti, and M. Di Rosa. 1992. Lipocortin and Vasocortin-2 species of antiinflammatory proteins mimicking the effect of glucocorticoid. Pharmacol. Res. 25:1-12.
52. 2 by "lipocortins" and calpactins. J. Biol. Chem. 262: 1698-1705.
53. 1 macrophage-like cells for enhanced arachidonic acid metabolism. J. Biol. Chem. 265:8658-8664.
54. 2. J. Biol. Chem. 266:14119-14127.
55. 2 in rat mesangial cells. Biochem. Biophys. Res. Commun. 174:268-275.
56. Prytz, H., J. Holst-Christensen, B. Korner, and H. Liehr. 1976. Portal venous and systemic endotoxemia in patients without liver disease and systemic endotoxemia in patients with cirrhosis. Scand. J. Gastroenterol. 11:857-863.
57. Clemente, C., J. Bosch, J. Rodes, V. Arroyo, A. Mas, and S. Maragall. 1977. Functional renal failure and hemorrhagic gastritis associated with endotoxemia in cirrhosis. Gut. 18:556-560.
58. 2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoids. FEBS Lett. 273:23-26.
59. 2 activity and sodium transport by angiotensin-(1-7). Kidney Int. 44:932-936.
60. Bosch, J., V. Arroyo, A. Betriu, A. Mas, F. Carrilho, F. Rivera, F.N. Lopez, and J. Rodès. 1980. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology. 78:92-99.
61. Nicholls, K.M., M.D. Shapiro, V.J. VanPutten, R. Kluge, H.M. Chung, D.G. Bichet, and R.W. Schrier. 1985. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates-normal clearance rats- and supressibility by central volume expansion. Cir. Res. 56:457-461.
62. 1-induced injury in the rat. Prostaglandins. 37:683-693.
63. Stachura, J., A. Tarnawski, K.J. Ivey, T. Mach, J. Bogdal, J. Szczudrawa, and B. Klimczyk. 1981. Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. Gastroenterology.. 81:211-217.
64. 2 on the liver and kidney. Prostaglandins. 21:97-102.
65. Bursch, W., and R. Schulte-Hermann. 1986. Cytoprotective effect of the prostacyclin derivative iloprost against liver cell death induced by hepatotoxin carbon tetrachloride and bromobenzene. Klin. Wochenschr. 64:47-50.
66. Guarner, F., N.K. Boughton-Smith, G.F. Blackwell, and S. Moncada. 1988. Reduction by prostacyclin of acetaminophen-induced liver toxicity in the mouse. Hepatology. 8:248-253.
67. Keppler, D., W. Hagmann, S. Rapp C. Denzlinger, and H.K. Koch. 1985. The relation of leukotrienes to liver injury. Hepatology. 5:883-891.
68. Tiegs, G., and A. Wendel. 1988. Leukotriene-mediated liver injury. Biochem. Pharmacol. 37:2569-2573.
69. Hagmann, W., A.M. Steffan, A. Kirn, and D. Keppler. 1987. Leukotriene as mediators in frog virus 3-induced hepatitis in rats. Hepatology. 7:732-736.
70. Wender, A., and G. Tiegs. 1987. Leukotriene D4 mediates galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol. 36:1867.
71. 4 in parenchymal and sinusoidal cells of the liver in rats treated simultaneously with D-galactosamine and endotoxin. Gastroenterol. Jpn. 24:640-645.
72. Uemura, M., U. Buchholz, H. Kojima, A. Keppler, P. Hafkemeyer, H. Fukui, T. Tsujii, and D. Keppler. 1994. Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology. 20:804-812.
73. Hashizume, M., K. Inokuchi, and K. Tanaka. 1985. The role of prostacyclin in patients with portal hypertension. Liver. 5:89-93.
74. Dunn, M.J. 1984. Role of eicosanoids in the control of renal function in severe hepatic disease. Gastroenterology. 87:1392-1395.
75. Brater, D.C., S.A. Anderson, and D.B. Cartwright. 1987. Reversible acute decrease in renal function by NSAlDs in cirrhosis. Am. J. Med. Sci. 294: 168-174.